The above reported findings suggest that the lower expression of HIPK2 in cancer tissues, compared to the normal ones, could serve as a novel biomarker of HCC progression due to the HIF-1-induced angiogenesis, although the mechanisms leading to HIPK2 downregulation (e.g., hypoxia or microRNAs) in HCC have not been elucidated and might deserve further studies. The gene discussed is HIPK2; the disease is hepatocellular carcinoma.